Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Eli Lilly & Co. stock underperforms Thursday when compared to competitors
Shares of Eli Lilly & Co. LLY slid 1.65% to $909.32 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 0.40% to 5,745.37 and the Dow Jones Industrial Average DJIA rising 0.62% to 42,175.11.
Prediction: This Is What Eli Lilly Stock Will Do Next (Hint: It's Not a Stock Split)
With a market capitalization of over $800 billion, Eli Lilly (NYSE: LLY) is the largest pharmaceutical company in the world. Much that is thanks to the rise of glucagon-like peptide-1 (GLP-1) agonists such as Mounjaro and Zepbound, which are fueling a new wave of growth for the company.
Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030
Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 598.51% and currently trading at $923.50. The company has been around since 1876 and the stock didn’t go public until 1952 but in the last 4 years,
Eli Lilly & Co. stock outperforms competitors on strong trading day
Eli Lilly & Co. closed $48.10 short of its 52-week high ($972.53), which the company achieved on August 22nd.
Is Eli Lilly Stock Still a Buy Near All-Time Highs?
Eli Lilly (LLY) stock is trading near its all-time highs, with the shares only about 5% away from the record levels set in August. With the shares up nearly 68% in the past 52 weeks and 58.5% year-to-date,
17h
Eli Lilly’s EBGLYSS offers long-term disease control in atopic dermatitis trial
Eli Lilly and Company has announced new long-term data from the ADjoin extension study, demonstrating that EBGLYSS ...
1d
Eli Lilly Stock Soars In 2024 On Weight Loss Drug Success, Now The Company Wants Medical Records Of Copycat Treatments
To fight off compounding pharmacies, Eli Lilly wants access to medical records of patients who used copycat products.
8h
Investigation Discloses Safety, Efficacy Concerns About Eli Lilly's Donanemab
An investigation, published in the journal The BMJ, found that the newly U.S. Food & Drug Administration-approved donanemab is linked ...
2d
on MSN
Eli Lilly's Alzheimer's drug approved in Japan
Eli Lilly said on Tuesday Japan's health ministry has approved donanemab, its drug for Alzheimer's disease, providing ...
2d
on MSN
Eli Lilly’s Alzheimer’s treatment Kisunla wins approval in Japan
Japan, with its rapidly aging population, is expected to have more than 5 million patients with dementia by 2030. Alzheimer’s ...
5d
Eli Lilly Is Finally Cheap, Warranting An Upgrade To Buy
Eli Lilly's long-term growth prospects are strong with improved supply, new growth opportunities, and competitive positioning ...
Zacks.com on MSN
1d
Eli Lilly Secures Approval for Alzheimer's Drug Kisunla in Japan
Japan is the second major market where LLY's Kisunla has been approved. The drug was first approved in the United States in ...
8d
Eli Lilly urges court to toss $183 mln Medicaid fraud judgment
Drugmaker Eli Lilly on Wednesday urged a federal appeals court to overturn a $183 million judgment against it in a case ...
Morningstar
3d
Obesity Drugs: Can New Firms Take Market Share From Eli Lilly and Novo Nordisk?
New public and private entrants are emerging to challenge the leading positions of Novo Nordisk NVO and
Eli
Lilly
LLY in ...
BioSpace
2d
Lilly and Novo Spend Billions to Expand Obesity Pipelines Beyond GLP-1s
Novo Nordisk and Eli Lilly are expected to rule the obesity market for a few more years without much challenge. To ensure ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
Japan
S&P 500 Index
Trade
Food and Drug Administration
Alzheimer's disease
Feedback